Report Adverse Event or Product Quality Complaint   

Header Logo
  • Prescribing Information
  • Therapy areas
    • All Therapeutic Areas
    • Cardiovascular, Renal and Metabolism
    • Immunology
    • Infection
    • Oncology
    • Rare Disease (Alexion)
    • Respiratory
  • Disease Education
  • Resources
    • Congress Library
    • Clinical Trials
    • Continuing Education
    • Patient Support
    • Pipeline
    • Oncology Pipeline Tool
  • Connect
    • Connect with an MSL
    • Connect with an MSL
    • Submit an Medical Information Request
    • Give Feedback

Search Medical Information

Login

Request a field medical follow-up

  • Home
  • Congress Library
  • ERS 2026

European Respiratory Society (ERS) Congress - 36th Annual Congress

5–9 September, 2026

  1. All
  2. Respiratory Unbranded
  3. BREZTRI/TRIXEO
  4. NOVELTY
  5. Tozorakimab
  6. TEZSPIRE (tezepelumab)
  7. FASENRA (benralizumab)

HTML

Mortality in patients with COPD exceeds prostate and breast cancer and is comparable to heart failure: A real-world study from England

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on clinical remission in inadequately controlled asthma: post hoc analyses of KALOS and LOGOS studies

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on time to first clinically important deterioration and number needed to treat for clinically important deterioration rate: tertiary analyses of KALOS and LOGOS studies

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on lung function and asthma exacerbations by persistent airflow limitation status: post hoc analyses of KALOS and LOGOS studies

PDF

Moderate-to-severe exacerbation risk among patients with COPD who had one recent exacerbation: a post-hoc analyses of the ETHOS and KRONOS studies

PDF

Baseline Chronic Airways Assessment Test score and severe cardiopulmonary events in the ETHOS study: a post-hoc analysis

HTML

Baseline chronic airways assessment test score and severe cardiopulmonary events in the ETHOS study: a post-hoc analysis

HTML

Burden of uncontrolled asthma+COPD: data from the NOVELTY Cohort

HTML

Tozorakimab modulates COPD airway biology beyond type 2 inflammation: insights from the Ph2 FRONTIER 4 study

PDF

Tozorakimab reduces the number of lung segments with mucus plugs in patients with COPD at high risk of exacerbations: integrated analysis of the replicate OBERON and TITANIA phase 3 studies

PDF

Standardized double read plus adjudication improves the reproducibility of CT mucus plug scoring in the LUNA ph3 Tozorakimab COPD clinical trials

PDF

Barriers in current and future care in people with COPD: CARINA study

PDF

Comparative disease burden in COPD patients on triple therapy versus GINA step 5 asthma patients

HTML

Predictors of inhaled corticosteroid, SABA and triple-therapy reduction following biologic initiation in severe asthma: real-world evidence from the International Severe Asthma Registry and Optimum Patient Care Research Database

HTML

Review of ICS, SABA and triple therapy prescribing following biologic initiation in severe asthma: real-world evidence from the International Severe Asthma Registry and Optimum Patient Care Research Database

HTML

Association between clinical and biological response to anti-IL5/5R biologic treatments in severe asthma

HTML

Predictors of relapse at 24 months among International Severe Asthma Registry patients in remission after 12 months on biologics

HTML

Relapse among International Severe Asthma Registry patients in remission 12 months after initiating biologics

HTML

Assessment of quality improvement impact on long-term oral corticosteroid (LTOCS) use in the International Severe Asthma Registry

PDF

Effect of tezepelumab on lung function in oral corticosteroid-dependent patients with severe asthma and comorbid CRSwNP or CRSsNP in the phase 3b WAYFINDER study

HTML

Phase IIb randomized study design to evaluate AZD6793, an oral IRAK4 inhibitor, in patients with moderate to very severe COPD

PDF

Disease stability at 52 weeks with tezepelumab in patients with moderate to very severe COPD: results from the phase 2a COURSE study

PDF

Effect of tezepelumab versus placebo on exacerbation-related systemic corticosteroid use and COPD-related healthcare utilization over time in patients with moderate to very severe COPD with elevated blood eosinophil counts (COURSE)

HTML

Nirsevimab and risk of hospitalization for wheezing in early childhood: a nationwide French health claims-based Cohort study

PDF

Baseline characteristics of patients with severe eosinophilic asthma (SEA) enrolled in the CHINOOK study: evaluating the effects of benralizumab on airway structure and lung function

HTML

Characterization of patients hospitalised for an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) in France: a national claims database study (OCTANS, part of the SIRIUS II program)

HTML

Remission with benralizumab in severe Asthma: real-world evidence from the French claims database (BENEFIT Study)

HTML

Characterization of adult Portuguese asthmatic population by GINA Step - findings from the Epi-Asthma Study

HTML

Targeted case-finding and proactive clinical management in a primary care setting reduces exacerbations in COPD patients with exacerbation history and scope for treatment optimisation: findings from the PREVAIL cluster randomised trial

HTML

Cardiovascular risk following COPD exacerbations in New Zealand: the nationwide EXACOS-CV NZ study

HTML

Longitudinal chronic bronchitis presence, but not mucus plugging, is associated with FEV1 decline in young adult smokers at risk of COPD: BEACON cohort

HTML

High burden of subsequent exacerbations among COPD patients on continuous triple inhaled therapy: a real-world swiss claims database analysis

HTML

Polygenic basis of lifetime lung function trajectories and spirometry patterns in the Tasmanian Longitudinal Health Study

HTML

Epidemiology and characteristics of Canadian adults with COPD who experience exacerbations while on inhaled triple therapy - An observational study of health administrative data

HTML

Societal costs of uncontrolled asthma in Sweden: a national web-based survey study

HTML

Unmet need in COPD patients receiving triple therapy: a nationwide claims analysis from the Czech Republic

HTML

One year is not enough: distinctive features of non-remitters in severe asthma treated with biologics

HTML

Clinical response to benralizumab in patients with severe eosinophilic asthma stratified by sex in routine clinical practice in Spain: GALERNA study

HTML

CD84 (SLAMF5): A new kid on the block in human ILC2 biology

PDF

Tozorakimab restores epithelial dysfunction in COPD

HTML

Intranasal recombinant mouse interleukin-13 administration as a model of chronic obstructive pulmonary disease and asthma

HTML

Atrial fibrillation as a cardiovascular comorbidity in RSV- and hMPV-Associated community-acquired pneumonia: clinical characteristics of virus-positive patients from the German CAPNETZ cohort

HTML

Translational in vitro platform to model lung involvement in RA ILD using patient serum

HTML

Using 129Xe-MRI to define an zone of uncertainty and interpret oscillometry results

HTML

Evolution of COPD hospitalizations in Spain, 2016-2024: sex-specific trends

HTML

Characterising extracellular matrix contributions to early origins of COPD using novel in vivo imaging and advanced CT techniques

HTML

Severe asthma across France in 2024: prevalence, care pathways, and treatment use - evidence from the ASMAP project

HTML

IRAK4 inhibition with AZD6793 preserves epithelial barrier function and dampens IL 1β-driven inflammation in primary human airway epithelium

HTML

Projecting Switzerland's LRTI and COPD burden: Restrospective nationwide hospital data identify drivers of severity and outcomes and forecast admissions through 2035.

HTML

Cost-effectiveness of a hypothetical concurrent SCS and maintenance high-dose ICS sparing in severe asthma: a China & UK payer perspective

HTML

Clinical bronchiectasis Pseudomonas aeruginosa isolates induce different neutrophil extracellular trap responses

HTML

BREATHE study: T2 biomarkers and treatment patterns in severe asthma patients with and without comorbid CRSwNP

HTML

Focal lung and lymph node eosinophilia as hubs of T2 and adaptive immunity in COPD

HTML

Antidepressant medication burden before and after prescription of biologics in patients with severe asthma

HTML

Plasma microbial cfDNA as a novel biomarker for the lung microbiome, inflammatory phenotypes, and exacerbation risk in COPD

HTML

Multimodal analyses show no association of Hedgehog pathway components with Idiopathic pulmonary fibrosis pathology

HTML

Algorithm based triage for COPD risk and follow up deficits in a digital health hotline application with near nationwide coverage in Sweden

HTML

NOX4 is expressed in aberrant basaloid epithelial cells and myofibroblasts in IPF lung tissue

HTML

Maximizing insight and efficiency: Comparison of Rate of decline in FVC and change from baseline in FVC analysed using frequentist and model-based approaches in idiopathic pulmonary fibrosis trials

HTML

AZD8965, a novel oral arginase inhibitor, shows consistent safety, tolerability and pharmacokinetic profile in healthy Chinese and Japanese participants: results from a Phase 1 study

HTML

Clinical response by baseline EOS and change in FeNO following benralizumab treatment in Chinese patients (pts) with severe eosinophilic asthma (SEA) on medium- or high-dose (MD/HD) ICS-LABA: Interim analysis of the phase 3b STEP study

HTML

A non-InteRventional, PrOspective study With bEnRalizumab to investigate clinical outcomes and medication in real-life: first insights from the AIR POWER study

HTML

Clinical response to benralizumab in patients with severe eosinophilic asthma in routine clinical practice in Spain according to BMI: ORBE II study

HTML

Baseline characteristics and clinical response after benralizumab initiation in patients with severe eosinophilic asthma according to severe disease duration: The GALERNA study

HTML

Patient motivators and barriers to biologic therapy initiation in moderate-to-severe asthma

HTML

Healthcare resource utilization (HCRU) in COPD during 52 weeks of treatment with budesonide/glycopyrronium/formoterol: results from the CHOROS ORION real-world study in Italy

HTML

Diabetes mellitus and prognosis in idiopathic pulmonary fibrosis: real-world evidence from a US multicenter cohort

HTML

Clinical, economic, and humanistic burden of Pseudomonas aeruginosa colonization in chronic respiratory diseases: a targeted literature review

HTML

A digital clinical decision support tool enables recruitment in primary care in a phase-3 COPD trial

HTML

Predicting asthma exacerbations and response to OCS using breath profiles

HTML

Improvement in 129Xe ventilation MRI and CT mucus plugging in severe asthma following tezepelumab

HTML

Mass cytometry and multi-omics profiling of the unified airway compartment reveals shared and distinct features in Type 2-high asthma and nasal polyposis

HTML

Airway microbiome dysbiosis is a predictor of failure to achieve clinical remission following biologic therapy

HTML

COPD exacerbation type according to previous COPD treatment

HTML

Cardiovascular events in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease

HTML

Characteristics of patients admitted to the hospital for a severe COPD exacerbation

HTML

Baseline characteristics of severe asthma patients initiating tezepelumab in the RAPSODI registry: a real-world comparison with the NAVIGATOR trial

HTML

A real-world quasi-controlled multicentre study evaluating the impact of benralizumab initiation on major outcomes in severe asthma

HTML

Acceptability and feasibility of oscillometry compared with spirometry in primary care

HTML

Digital decision support improves asthma control in Spanish primary care: OptimAIR study

HTML

Opportunities for optimization of asthma management by using the AsthmaOptimiser in primary care: the multi-country OptimAIR study

HTML

Improved asthma symptoms following digital support in Chilean primary care: OptimAIR study

HTML

Impact of the digital decision-support tool AsthmaOptimiser on asthma outcomes in Argentina: the OptimAIR study

HTML

Diagnostic classification in primary care using "Breathlessness Diagnostics in a Box" (BiaB)

HTML

Temporal validation of COPD exacerbation risk prediction using routinely collected healthcare data

HTML

Impact of a structured cardiopulmonary risk-focused COPD review in primary care

HTML

Type 2 biomarker stratification of clinical remission with tezepelumab: the TERESA study

HTML

Prospective evaluation of clinical and complete remission with tezepelumab: the TERESA study

HTML

Dissociation between spirometric recovery and persistent small airway dysfunction after acute asthma exacerbations in a prospective cohort study

HTML

Predictors of weight variations in patients with COPD: a longitudinal cohort study

HTML

Modeling COPD worsening: a longitudinal cohort study

HTML

Hypercapnia is associated with lower muscle mass in Chronic Obstructive Pulmonary Disease (COPD)

HTML

Impact of early versus delayed biologic therapy initiation on severe asthma outcomes

HTML

Sex-Related clinical characteristics and COPD prevalence in an active smoking population

HTML

Timing of triple therapy after exacerbation and risk of exacerbations, cardiovascular events and mortality: An emulated trial in the Swedish National Airway Register

HTML

Sputum biomarkers of eosinophil degranulation in COPD; relationship with eosinophil cell counts.

HTML

Predicting asthma exacerbations and response to OCS using breath profiles

HTML

Changes in nocturnal vital parameters during the treatment of acute asthma exacerbations: a continuous home monitoring study

HTML

Tezepelumab treatment of severe asthma reduces upper airway expression of alarmin cytokines TSLP, IL-25 and IL-33: An observational pilot study

PDF

Tozorakimab to prevent COPD exacerbations: results from the replicate OBERON and TITANIA phase 3 studies

HTML

Mortality in patients with COPD exceeds prostate and breast cancer and is comparable to heart failure: A real-world study from England

PDF

Barriers in current and future care in people with COPD: CARINA study

PDF

Comparative disease burden in COPD patients on triple therapy versus GINA step 5 asthma patients

HTML

Predictors of inhaled corticosteroid, SABA and triple-therapy reduction following biologic initiation in severe asthma: real-world evidence from the International Severe Asthma Registry and Optimum Patient Care Research Database

HTML

Review of ICS, SABA and triple therapy prescribing following biologic initiation in severe asthma: real-world evidence from the International Severe Asthma Registry and Optimum Patient Care Research Database

HTML

Association between clinical and biological response to anti-IL5/5R biologic treatments in severe asthma

HTML

Predictors of relapse at 24 months among International Severe Asthma Registry patients in remission after 12 months on biologics

HTML

Relapse among International Severe Asthma Registry patients in remission 12 months after initiating biologics

HTML

Assessment of quality improvement impact on long-term oral corticosteroid (LTOCS) use in the International Severe Asthma Registry

HTML

Characterization of patients hospitalised for an Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD) in France: a national claims database study (OCTANS, part of the SIRIUS II program)

HTML

Characterization of adult Portuguese asthmatic population by GINA Step - findings from the Epi-Asthma Study

HTML

Targeted case-finding and proactive clinical management in a primary care setting reduces exacerbations in COPD patients with exacerbation history and scope for treatment optimisation: findings from the PREVAIL cluster randomised trial

HTML

Cardiovascular risk following COPD exacerbations in New Zealand: the nationwide EXACOS-CV NZ study

HTML

Longitudinal chronic bronchitis presence, but not mucus plugging, is associated with FEV1 decline in young adult smokers at risk of COPD: BEACON cohort

HTML

Polygenic basis of lifetime lung function trajectories and spirometry patterns in the Tasmanian Longitudinal Health Study

HTML

Epidemiology and characteristics of Canadian adults with COPD who experience exacerbations while on inhaled triple therapy - An observational study of health administrative data

HTML

One year is not enough: distinctive features of non-remitters in severe asthma treated with biologics

HTML

CD84 (SLAMF5): A new kid on the block in human ILC2 biology

HTML

Intranasal recombinant mouse interleukin-13 administration as a model of chronic obstructive pulmonary disease and asthma

HTML

Atrial fibrillation as a cardiovascular comorbidity in RSV- and hMPV-Associated community-acquired pneumonia: clinical characteristics of virus-positive patients from the German CAPNETZ cohort

HTML

Translational in vitro platform to model lung involvement in RA ILD using patient serum

HTML

Using 129Xe-MRI to define an zone of uncertainty and interpret oscillometry results

HTML

Evolution of COPD hospitalizations in Spain, 2016-2024: sex-specific trends

HTML

Characterising extracellular matrix contributions to early origins of COPD using novel in vivo imaging and advanced CT techniques

HTML

Severe asthma across France in 2024: prevalence, care pathways, and treatment use - evidence from the ASMAP project

HTML

Projecting Switzerland's LRTI and COPD burden: Restrospective nationwide hospital data identify drivers of severity and outcomes and forecast admissions through 2035.

HTML

Cost-effectiveness of a hypothetical concurrent SCS and maintenance high-dose ICS sparing in severe asthma: a China & UK payer perspective

HTML

Clinical bronchiectasis Pseudomonas aeruginosa isolates induce different neutrophil extracellular trap responses

HTML

BREATHE study: T2 biomarkers and treatment patterns in severe asthma patients with and without comorbid CRSwNP

HTML

Focal lung and lymph node eosinophilia as hubs of T2 and adaptive immunity in COPD

HTML

Antidepressant medication burden before and after prescription of biologics in patients with severe asthma

HTML

Plasma microbial cfDNA as a novel biomarker for the lung microbiome, inflammatory phenotypes, and exacerbation risk in COPD

HTML

Multimodal analyses show no association of Hedgehog pathway components with Idiopathic pulmonary fibrosis pathology

HTML

Algorithm based triage for COPD risk and follow up deficits in a digital health hotline application with near nationwide coverage in Sweden

HTML

NOX4 is expressed in aberrant basaloid epithelial cells and myofibroblasts in IPF lung tissue

HTML

Maximizing insight and efficiency: Comparison of Rate of decline in FVC and change from baseline in FVC analysed using frequentist and model-based approaches in idiopathic pulmonary fibrosis trials

HTML

Patient motivators and barriers to biologic therapy initiation in moderate-to-severe asthma

HTML

Diabetes mellitus and prognosis in idiopathic pulmonary fibrosis: real-world evidence from a US multicenter cohort

HTML

Clinical, economic, and humanistic burden of Pseudomonas aeruginosa colonization in chronic respiratory diseases: a targeted literature review

HTML

Mass cytometry and multi-omics profiling of the unified airway compartment reveals shared and distinct features in Type 2-high asthma and nasal polyposis

HTML

Airway microbiome dysbiosis is a predictor of failure to achieve clinical remission following biologic therapy

HTML

COPD exacerbation type according to previous COPD treatment

HTML

Cardiovascular events in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease

HTML

Acceptability and feasibility of oscillometry compared with spirometry in primary care

HTML

Digital decision support improves asthma control in Spanish primary care: OptimAIR study

HTML

Opportunities for optimization of asthma management by using the AsthmaOptimiser in primary care: the multi-country OptimAIR study

HTML

Improved asthma symptoms following digital support in Chilean primary care: OptimAIR study

HTML

Impact of the digital decision-support tool AsthmaOptimiser on asthma outcomes in Argentina: the OptimAIR study

HTML

Diagnostic classification in primary care using "Breathlessness Diagnostics in a Box" (BiaB)

HTML

Temporal validation of COPD exacerbation risk prediction using routinely collected healthcare data

HTML

Impact of a structured cardiopulmonary risk-focused COPD review in primary care

HTML

Dissociation between spirometric recovery and persistent small airway dysfunction after acute asthma exacerbations in a prospective cohort study

HTML

Predictors of weight variations in patients with COPD: a longitudinal cohort study

HTML

Modeling COPD worsening: a longitudinal cohort study

HTML

Hypercapnia is associated with lower muscle mass in Chronic Obstructive Pulmonary Disease (COPD)

HTML

Impact of early versus delayed biologic therapy initiation on severe asthma outcomes

HTML

Sex-Related clinical characteristics and COPD prevalence in an active smoking population

HTML

Timing of triple therapy after exacerbation and risk of exacerbations, cardiovascular events and mortality: An emulated trial in the Swedish National Airway Register

HTML

Sputum biomarkers of eosinophil degranulation in COPD; relationship with eosinophil cell counts.

HTML

Predicting asthma exacerbations and response to OCS using breath profiles

HTML

Changes in nocturnal vital parameters during the treatment of acute asthma exacerbations: a continuous home monitoring study

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on clinical remission in inadequately controlled asthma: post hoc analyses of KALOS and LOGOS studies

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on time to first clinically important deterioration and number needed to treat for clinically important deterioration rate: tertiary analyses of KALOS and LOGOS studies

PDF

Budesonide/glycopyrronium/formoterol fumarate dihydrate effects on lung function and asthma exacerbations by persistent airflow limitation status: post hoc analyses of KALOS and LOGOS studies

PDF

Moderate-to-severe exacerbation risk among patients with COPD who had one recent exacerbation: a post-hoc analyses of the ETHOS and KRONOS studies

PDF

Baseline Chronic Airways Assessment Test score and severe cardiopulmonary events in the ETHOS study: a post-hoc analysis

HTML

Healthcare resource utilization (HCRU) in COPD during 52 weeks of treatment with budesonide/glycopyrronium/formoterol: results from the CHOROS ORION real-world study in Italy

HTML

A digital clinical decision support tool enables recruitment in primary care in a phase-3 COPD trial

HTML

Burden of uncontrolled asthma+COPD: data from the NOVELTY Cohort

HTML

Tozorakimab modulates COPD airway biology beyond type 2 inflammation: insights from the Ph2 FRONTIER 4 study

PDF

Tozorakimab reduces the number of lung segments with mucus plugs in patients with COPD at high risk of exacerbations: integrated analysis of the replicate OBERON and TITANIA phase 3 studies

PDF

Standardized double read plus adjudication improves the reproducibility of CT mucus plug scoring in the LUNA ph3 Tozorakimab COPD clinical trials

PDF

Tozorakimab restores epithelial dysfunction in COPD

PDF

Tozorakimab to prevent COPD exacerbations: results from the replicate OBERON and TITANIA phase 3 studies

PDF

Effect of tezepelumab on lung function in oral corticosteroid-dependent patients with severe asthma and comorbid CRSwNP or CRSsNP in the phase 3b WAYFINDER study

PDF

Disease stability at 52 weeks with tezepelumab in patients with moderate to very severe COPD: results from the phase 2a COURSE study

PDF

Effect of tezepelumab versus placebo on exacerbation-related systemic corticosteroid use and COPD-related healthcare utilization over time in patients with moderate to very severe COPD with elevated blood eosinophil counts (COURSE)

HTML

Improvement in 129Xe ventilation MRI and CT mucus plugging in severe asthma following tezepelumab

HTML

Baseline characteristics of severe asthma patients initiating tezepelumab in the RAPSODI registry: a real-world comparison with the NAVIGATOR trial

HTML

Type 2 biomarker stratification of clinical remission with tezepelumab: the TERESA study

HTML

Prospective evaluation of clinical and complete remission with tezepelumab: the TERESA study

HTML

Tezepelumab treatment of severe asthma reduces upper airway expression of alarmin cytokines TSLP, IL-25 and IL-33: An observational pilot study

PDF

Baseline characteristics of patients with severe eosinophilic asthma (SEA) enrolled in the CHINOOK study: evaluating the effects of benralizumab on airway structure and lung function

HTML

Remission with benralizumab in severe Asthma: real-world evidence from the French claims database (BENEFIT Study)

HTML

Clinical response to benralizumab in patients with severe eosinophilic asthma stratified by sex in routine clinical practice in Spain: GALERNA study

HTML

Clinical response by baseline EOS and change in FeNO following benralizumab treatment in Chinese patients (pts) with severe eosinophilic asthma (SEA) on medium- or high-dose (MD/HD) ICS-LABA: Interim analysis of the phase 3b STEP study

HTML

A non-InteRventional, PrOspective study With bEnRalizumab to investigate clinical outcomes and medication in real-life: first insights from the AIR POWER study

HTML

Clinical response to benralizumab in patients with severe eosinophilic asthma in routine clinical practice in Spain according to BMI: ORBE II study

HTML

Baseline characteristics and clinical response after benralizumab initiation in patients with severe eosinophilic asthma according to severe disease duration: The GALERNA study

HTML

A real-world quasi-controlled multicentre study evaluating the impact of benralizumab initiation on major outcomes in severe asthma

Disclaimer

Some content may have changed since publication. Some links may require registration/login to access the content. Any attached publications and/or any tables or figures derived from the publications are copyright-protected works. AstraZeneca has obtained permission from the copyright owner to use this work on this site. You may not reproduce, prepare derivative works from, display or distribute this work unless you obtain the permission of the copyright owner, or as otherwise might be permitted by law.

Connessiallasalute.it

This site is intended for healthcare professionals practicing in the US.
©2026 AstraZeneca. All rights reserved.

US-115625
Last Updated 9/26

Contact Us

About Us

AstraZeneca-US.com

Other Countries

Grant Opportunities  

Survey Feedback

Your Privacy Choice

Consumer Health Data
Privacy Notice

Privacy Notice | Legal Notice | Cookie Preferences

Welcome to AstraZeneca Medical Information

The information provided on this site is intended for use by healthcare professionals practicing in the US. The dissemination of this information may be subject to different medical and regulatory requirements in other countries.

 

This web site is intended to help healthcare professionals practicing in the US and AstraZeneca authorized persons find scientifically balanced, evidence-based information about AstraZeneca drugs, submit a question, ask for field medical follow-up, and explore links to professional and patient support resources.

 

Are you a healthcare professional practicing in the United States?

I am an AstraZeneca authorized person   What is an AstraZeneca authorized person?
This website is only intended for healthcare professionals practicing in the United States and authorized AstraZeneca personnel. AstraZeneca US Headquarters personnel and US Field Medical personnel are authorized to browse and search the database for their own background knowledge and insight. US Field Sales personnel should not access or browse this site. None of the content of this site should be directly linked or distributed without approval.
I am not a healthcare professional practicing in the United States